Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-07-15 Sale |
2020-07-17 5:23 pm |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
13,000 | $68 | $884,000 | 47,000 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-21 Option Award |
2025-02-25 4:10 pm |
N/A 2035-02-21 |
Inhibikase Therapeutics Inc. | IKT | Cabell Christopher President & Head of R&D |
1,100,705 | $0 | 1,100,705 (Direct) |
View |
| 2023-05-18 Option Award |
2023-05-22 9:15 pm |
N/A N/A |
Zura Bio Ltd | ZURA | Cabell Christopher CMO & Head of R&D |
162,060 | $0 | 162,060 (Direct) |
View |
Ownership |
2023-03-21 7:33 pm |
N/A 2023-03-15 |
Zura Bio Ltd | ZURA | Cabell Christopher EVP and CMO |
0 | $0 | 270,100 (Direct) |
View |
| 2023-01-26 Option Award |
2023-01-30 4:05 pm |
N/A 2033-01-26 |
Pulmatrix Inc. | PULM | Cabell Christopher Director |
1,700 | $0 | 1,700 (Direct) |
View |
| 2022-01-27 Option Award |
2022-01-31 09:36 am |
N/A 2032-01-27 |
Pulmatrix Inc. | PULM | Cabell Christopher Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2021-01-28 Option Award |
2021-02-01 9:45 pm |
N/A 2031-01-28 |
Pulmatrix Inc. | PULM | Cabell Christopher Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2020-11-25 Exercise |
2020-11-30 4:01 pm |
N/A 2022-01-03 |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
2,500 | $0 | 6,401 (Direct) |
View |
| 2020-11-25 Tax Withholding |
2020-11-30 4:01 pm |
N/A N/A |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
1,099 | $65.5 | 6,401 (Direct) |
View |
| 2020-07-15 Exercise |
2020-07-17 5:23 pm |
N/A 2024-11-15 |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
13,000 | $0 | 47,000 (Direct) |
View |
| 2020-07-15 Exercise |
2020-07-17 5:23 pm |
N/A N/A |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
13,000 | $26.28 | 47,000 (Direct) |
View |
| 2020-06-23 Option Award |
2020-06-25 9:46 pm |
N/A 2030-06-23 |
Pulmatrix Inc. | PULM | Cabell Christopher Director |
30,000 | $0 | 30,000 (Direct) |
View |
| 2020-06-12 Option Award |
2020-06-16 7:25 pm |
N/A 2027-06-12 |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
20,000 | $0 | 20,000 (Direct) |
View |
Ownership |
2020-06-16 7:23 pm |
N/A 2024-11-15 |
ARENA PHARMACEUTICALS INC | ARNA | Cabell Christopher EVP, Head of R&D, and CMO |
0 | $0 | 212,500 (Direct) |
View |